Role of PFDN and its subunits in tumorigenesis and tumor development

Abstract

Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.

References27

[1]	Vainberg IE, Lewis SA, Rommelaere H, et al. Prefoldin, a chape-rone that delivers unfolded proteins to cytosolic chaperonin[J].Cell,1998,93(5): 863-873. DOI:10.1016/s0092-8674(00)81446-4. pmid:9630229
[2]	Gestaut D, Roh SH, Ma BX, et al. The chaperonin TRiC/CCT associates with prefoldin through a conserved electrostatic interface essential for cellular proteostasis[J].Cell,2019,177(3): 751-765.e15. DOI:10.1016/j.cell.2019.03.012. pmid:30955883
[3]	Tahmaz I, Shahmoradi Ghahe S, Topf U. Prefoldin function in cellular protein homeostasis and human diseases[J].Front Cell Dev Biol,2021,9: 816214. DOI:10.3389/fcell.2021.816214.
[4]	Wang P, Zhao J, Yang X, et al. PFDN1, an indicator for colorectal cancer prognosis, enhances tumor cell proliferation and motility through cytoskeletal reorganization[J].Med Oncol,2015,32(12): 264. DOI:10.1007/s12032-015-0710-z. pmid:26553318
[5]	Miyazawa M, Tashiro E, Kitaura H, et al. Prefoldin subunits are protected from ubiquitin-proteasome system-mediated degradation by forming complex with other constituent subunits[J].J Biol Chem,2011,286(22): 19191-19203. DOI:10.1074/jbc.M110.216259. pmid:21478150
[6]	Peñate X, Praena-Fernández JM, Romero Pareja P, et al. Over-expression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer[J].Cancers (Basel),2020,12(4): 1052. DOI:10.3390/cancers12041052.
[7]	Zhao HC, Chen CZ, Yang CL, et al. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy[J].Pathol Res Pract,2022,232: 153808. DOI:10.1016/j.prp.2022.153808.
[8]	Jiang LL, Liu J. Prefoldin 6 promotes glioma progression via the AKT signalling pathway[J].Cell Biol Int,2023,47(1): 52-62. DOI:10.1002/cbin.11895.
[9]	Yang KY, Wu ZJ, Zhang H, et al. Glioma targeted therapy: insight into future of molecular approaches[J].Mol Cancer,2022,21(1): 39. DOI:10.1186/s12943-022-01513-z. pmid:35135556
[10]	Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012—2016[J].Neuro Oncol,2019,21(Suppl 5): v1-v100. DOI:10.1093/neuonc/noz150.
[11]	Cai JY, Hu YY, Ye Z, et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour micro-environment in lower-grade glioma[J].Front Immunol,2022,13: 1011757. DOI:10.3389/fimmu.2022.1011757.
[12]	Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022[J].CA Cancer J Clin,2022,72(6): 524-541. DOI:10.3322/caac.21754.
[13]	Sarhangi N, Hajjari S, Heydari SF, et al. Breast cancer in the era of precision medicine[J].Mol Biol Rep,2022,49(10): 10023-10037. DOI:10.1007/s11033-022-07571-2. pmid:35733061
[14]	Hashemi M, Arani HZ, Orouei S, et al. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions[J].Biomed Pharmacother,2022,155: 113774. DOI:10.1016/j.biopha.2022.113774.
[15]	黄超有, 李玺, 韩铮, 等. Prefoldin 1对乳腺癌BT474细胞上皮-间充质转化的影响[J].实用医学杂志,2019,35(1): 47-50. DOI:10.3969/j.issn.1006-5725.2019.01.010.
[16]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660.
[17]	Li YT, Yan BS, He SM. Advances and challenges in the treatment of lung cancer[J].Biomed Pharmacother,2023,169: 115891. DOI:10.1016/j.biopha.2023.115891.
[18]	Wang D, Shi W, Tang Y, et al. Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression[J].Oncogene,2017,36(7): 885-898. DOI:10.1038/onc.2016.257. pmid:27694898
[19]	Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives[J].J Hematol Oncol,2023,16(1): 57. DOI:10.1186/s13045-023-01451-3.
[20]	于晓鹏, 冯青青, 赵文飞, 等. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J].国际肿瘤学杂志,2023,50(10): 631-635. DOI:10.3760/cma.j.cn371439-20230428-00120.
[21]	Zhou C, Guo ZY, Xu LQ, et al. PFND1 predicts poor prognosis of gastric cancer and promotes cell metastasis by activating the Wnt/β-catenin pathway[J].Onco Targets Ther,2020,13: 3177-3186. DOI:10.2147/OTT.S236929.
[22]	Malagoli Tagliazucchi G, Wiecek AJ, Withnell E, et al. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer[J].Nat Commun,2023,14(1): 789. DOI:10.1038/s41467-023-36439-7. pmid:36774358
[23]	Chen TN, He QM, Xiang ZX, et al. Identification and validation of key genes of differential correlations in gastric cancer[J].Front Cell Dev Biol,2021,9: 801687. DOI:10.3389/fcell.2021.801687.
[24]	He QM, Ding ZY, Chen TN, et al. PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer[J].Front Oncol,2023,13: 1164070. DOI:10.3389/fonc.2023.1164070.
[25]	Shao YF, Yesseyeva G, Zhi YH, et al. Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer[J].Genomics,2024,116(2): 110821. DOI:10.1016/j.ygeno.2024.110821.
[26]	Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J].Biochim Biophys Acta Rev Cancer,2020,1873(1):188314. DOI:10.1016/j.bbcan.2019.188314.
[27]	Ke SJ, Lu SN, Wang CQ, et al. Comprehensive analysis of the prognostic value and functions of prefoldins in hepatocellular carcinoma[J].Front Mol Biosci,2022,9: 957001. DOI:10.3389/fmolb.2022.957001.

Role of PFDN and its subunits in tumorigenesis and tumor development

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References27

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[6]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[7]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[8]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[9]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[10]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[11]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[12]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[13]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[14]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.
[15]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng.Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor[J]. Journal of International Oncology, 2024, 51(5): 298-302.